References

Follicular lymphoma: 2023 update on diagnosis and management

10.1002/ajh.26737 · 2022 · External reference

An updated understanding of follicular lymphoma transformation

10.1182/blood.2024026016 · 2025 · External reference

Early rituximab monotherapy versus watchful waiting for advanced stage, asymptomatic, low tumour burden follicular lymphoma: long-term results of a randomised, phase 3 trial

10.1016/s2352-3026(25)00034-1 · 2025 · External reference

Frontline treatment of follicular lymphoma: what will it take to change current practice?

10.1182/blood.2024026019 · 2025 · External reference

Bendamustine plus rituximab versus CHOP plus rituximab as first-line treatment for patients with indolent and mantle-cell lymphomas: an open-label, multicentre, randomised, phase 3 non-inferiority trial

10.1016/s0140-6736(12)61763-2 · 2013 · External reference

First-line treatment of patients with indolent non-hodgkin lymphoma or mantle-cell lymphoma with bendamustine plus rituximab versus R-CHOP or R-CVP: results of the BRIGHT 5-year follow-up study

10.1200/jco.18.00605 · 2019 · External reference

Evaluating the role of CAR-T cell therapy in the context of current therapy options for patients with relapsed or refractory follicular Y lymphoma

10.1016/j.jtct.2025.06.013 · 2025 · External reference

Early relapse of follicular lymphoma after rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone defines patients at high risk for death: an analysis from the national LymphoCare study

10.1200/jco.2014.59.7534 · 2015 · External reference

Rates and outcomes of follicular lymphoma transformation in the immunochemotherapy era: a report from the university of iowa/mayo clinic specialized program of research excellence molecular epidemiology resource

10.1200/jco.2012.48.3990 · 2013 · External reference

Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

10.1016/s2352-3026(22)00033-3 · 2022 · External reference

Follicular lymphoma: current therapeutic landscape and future prospects

10.1002/hon.70070 · 2025 · External reference

Long-term 3-year follow-up of mosunetuzumab in relapsed or refractory follicular lymphoma after ≥2 prior therapies

10.1182/blood.2024025454 · 2025 · External reference

Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

10.1038/s41591-021-01622-0 · 2022 · External reference

Axicabtagene ciloleucel in relapsed or refractory indolent non-hodgkin lymphoma (ZUMA-5): a single-arm, multicentre, phase 2 trial

10.1016/s1470-2045(21)00591-x · 2022 · External reference

Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

10.1038/s41591-024-02986-9 · 2024 · External reference

Barriers to chimeric antigen receptor T-cell (CAR-T) therapies in clinical practice

10.1007/s40290-022-00428-w · 2022 · External reference

Tracing the development of CAR-T cell design: from concept to next-generation platforms

10.3389/fimmu.2025.1615212 · 2025 · External reference

CAR-T cell therapy in cancer immunotherapy – biology, clinical successes, and emerging challenges: a review

10.17305/bb.2026.14266 · 2026 · External reference

Tisa-cel and axi-cel CAR structure influences the development of resistance to CD19-CAR-T therapy

10.1038/s41375-026-03081-3 · 2026 · External reference

Newly diagnosed and relapsed follicular lymphoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up

10.1016/j.annonc.2020.11.008 · 2021 · External reference

Complexities in comparing the impact of costimulatory domains on approved CD19 CAR functionality

10.1186/s12967-023-04372-4 · 2023 · External reference

A comparison of chimeric antigen receptors containing CD28 versus 4-1BB costimulatory domains

10.1038/s41571-021-00530-z · 2021 · External reference

Three-year follow-up analysis of axicabtagene ciloleucel in relapsed/refractory indolent non-hodgkin lymphoma (ZUMA-5)

10.1182/blood.2023021243 · 2024 · External reference

Five-year follow-up analysis of ZUMA-5: axicabtagene ciloleucel in relapsed/refractory indolent non-hodgkin lymphoma

10.1200/jco-25-00668 · 2025 · External reference

Clinical, tumor, and product features associated with outcomes after axicabtagene ciloleucel therapy in follicular lymphoma

10.1172/jci181893 · 2025 · External reference

Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

10.1182/blood.2023021567 · 2024 · External reference

Efficacy comparison of tisagenlecleucel vs usual care in patients with relapsed or refractory follicular lymphoma

10.1182/bloodadvances.2022008150 · 2022 · External reference

Effectiveness of tisagenlecleucel versus real-world standard of care in relapsed/refractory follicular lymphoma

10.57264/cer-2022-0173 · 2023 · External reference

Real-word experience of CAR T-cells in patients with relapsed/refractory follicular lymphoma : a descart registry analysis from the lysa

10.1182/blood-2023-184653 · 2023 · External reference

Real-world experience with CAR -T therapy in relapsed and refractory follicular lymphoma

10.1111/bjh.70025 · 2025 · External reference

Comparative effectiveness of axicabtagene ciloleucel vs historical standard-of-care in patients with relapsed or refractory follicular lymphoma: an analysis of CIBMTR and SCHOLAR-5 data

10.1182/blood-2023-178629 · 2023 · External reference

Matching-adjusted indirect comparisons of axicabtagene ciloleucel to mosunetuzumab for the treatment of relapsed/refractory follicular lymphoma

10.1016/j.jtct.2024.06.016 · 2024 · External reference

Matching-adjusted indirect comparison of efficacy and safety of lisocabtagene maraleucel and mosunetuzumab for the treatment of third-line or later relapsed or refractory follicular lymphoma

10.1186/s40164-025-00610-1 · 2025 · External reference

Preliminary efficacy and safety of relmacabtagene autoleucel (carteyva) in adults with relapsed/refractory follicular lymphoma in China: a phase I/II clinical trial

10.1002/ajh.26711 · 2022 · External reference

Two-year follow-up of relmacabtagene autoleucel in relapsed or refractory follicular lymphoma in RELIANCE study

10.1111/bjh.20122 · 2025 · External reference

Survival benefit of relmacabtagene autoleucel versus usual care in relapsed/refractory follicular lymphoma: a matching-adjusted indirect analysis

10.1002/hon.70051 · 2025 · External reference

Efficacy and safety of the academic anti-CD19 chimeric antigen receptor T-cell product varnimcabtagene autoleucel for the treatment of relapsed/refractory follicular lymphoma

10.1002/hem3.70166 · 2025 · External reference

T-cell responses against CD19-targeted CAR T cells varnimcabtagene autoleucel (ARI-0001): implications for immune response and therapy outcomes

10.1136/jitc-2024-010792 · 2025 · External reference

Efficacy and safety of a third generation CD20 CAR-T (MB-106) for treatment of relapsed/refractory indolent B-cell non-hodgkin lymphoma: phase-1 results from a multicenter trial

10.1182/blood-2023-175007 · 2023 · External reference

Safety and efficacy of third generation CD20 targeted CAR-T (MB-106) for treatment of relapsed/refractory B-NHL and CLL

10.1182/blood-2021-149181 · 2021 · External reference

High efficacy and favorable safety of 3rd generation cd20 car-t (mb-106) for outpatient treatment of follicular lymphoma (fl)—results of a single-institution trial

10.1002/hon.3163_49 · 2023 · External reference

CD22-directed CAR T-cell therapy achieves complete remission in CD19-directed CAR T-cell refractory follicular and mantle cell lymphoma

2024 · External reference

CD22-directed CAR T-cell therapy achieves complete remission in CD19-directed CAR T-cell refractory follicular and mantle cell lymphoma with superior safety and absence of neurotoxicity

10.1016/j.jtct.2025.01.599 · 2025 · External reference

Chimeric antigen receptor T cells to target CD79b in B-cell lymphomas

10.1136/jitc-2023-007515 · 2023 · External reference

Chimeric antigen receptor T cells targeting CD79b show efficacy in lymphoma with or without cotargeting CD19

10.1158/1078-0432.ccr-19-1337 · 2019 · External reference

BAFF and BAFF-receptor in B cell selection and survival

10.3389/fimmu.2018.02285 · 2018 · External reference

Favorable safety profile and durable responses to pmb-CT01 (BAFFR-CAR T cell) therapy in patients with B-cell lymphomas ineligible for or who failed CD19-targeted therapy, including CD19-negative disease

10.1182/blood-2024-198416 · 2024 · External reference

CXCL13-CXCR5 axis: regulation in inflammatory diseases and cancer

2022 · External reference

CXCR5 CAR-T cells simultaneously target B cell non-hodgkin’s lymphoma and tumor-supportive follicular T helper cells

10.1038/s41467-020-20488-3 · 2021 · External reference

CD70-targeted CAR-T/NK therapy: Rationale, advances, and future directions

10.1016/j.tranon.2025.102555 · 2025 · External reference

CD70-targeting CAR-T cells have potential activity against CD19-negative B-cell lymphoma

10.1002/cac2.12201 · 2021 · External reference

CAR-T cell therapy: current limitations and potential strategies

10.1038/s41408-021-00459-7 · 2021 · External reference

Efficacy and safety of a novel CD19, CD22 dual-targeted fully human loop bi-CAR-T for the treatment of relapsed/refractory B cell non-hodgkin lymphoma

10.1186/s12967-025-06567-3 · 2025 · External reference

A phase 1 trial of prizloncabtagene autoleucel, a CD19/CD20 CAR T-cell therapy for relapsed/refractory B-cell non-Hodgkin lymphoma

10.1182/blood.2024026401 · 2025 · External reference

BCMA-targeted immunotherapy for multiple myeloma

10.1186/s13045-020-00962-7 · 2020 · External reference

ARI0003: Co-transduced CD19/BCMA dual-targeting CAR-T cells for the treatment of non-hodgkin lymphoma

10.1016/j.ymthe.2024.11.028 · 2025 · External reference

CAR-T cell combination therapies in hematologic malignancies

10.1186/s40164-024-00536-0 · 2024 · External reference

Current and future therapies for follicular lymphoma

10.1186/s40164-024-00551-1 · 2024 · External reference

Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-hodgkin lymphoma

10.1111/cas.14915 · 2021 · External reference

Acalabrutinib in combination with anti-CD19 chimeric antigen receptor T-cell therapy in relapsed/refractory B-cell lymphoma: a phase I/II study of safety, efficacy and immune correlative analysis

10.1016/j.jtct.2023.12.049 · 2024 · External reference

Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL

10.1007/s00277-023-05255-w · 2023 · External reference

BTK inhibitor synergizes with CD19-targeted chimeric antigen receptor-T cells in patients with relapsed or refractory B-cell lymphoma: an open-label pragmatic clinical trial

10.1182/blood-2024-205304 · 2024 · External reference

Efficient combination of radiotherapy and CAR-T – a systematic review

10.1016/j.biopha.2024.116532 · 2024 · External reference

Don’t put the CART before the horse: the role of radiation therapy in peri-CAR T-cell therapy for aggressive B-cell non-hodgkin lymphoma

10.1016/j.ijrobp.2022.12.017 · 2023 · External reference

Bridging radiotherapy before chimeric antigen receptor T cells for B-cell lymphomas: an ILROG multicenter study

10.1182/bloodadvances.2025015855 · 2025 · External reference

Bridging transplantation and immunotherapy: clinical promise of autologous stem cell transplantation with chimeric antigen receptor T-cell therapy

10.21147/j.issn.1000-9604.2025.04.03 · 2025 · External reference

Combination autologous stem cell transplantation with chimeric antigen receptor T-cell therapy for refractory/relapsed B-cell lymphoma: a single-arm clinical study

2025 · External reference

CD20-bispecific antibodies improve response to CD19-CAR T cells in lymphoma in vitro and CLL in vivo models

10.1182/blood.2023022682 · 2024 · External reference

CAR-T cells secreting BiTEs circumvent antigen escape without detectable toxicity

10.1038/s41587-019-0192-1 · 2019 · External reference

CD22 CAR-T cells secreting CD19 T-cell engagers for improved control of B-cell acute lymphoblastic leukemia progression

10.1136/jitc-2024-009048 · 2025 · External reference

CAR race to cancer immunotherapy: from CAR T, CAR NK to CAR macrophage therapy

10.1186/s13046-022-02327-z · 2022 · External reference

Allogeneic chimeric antigen receptor T-cell products cemacabtagene ansegedleucel/ALLO-501 in relapsed/refractory large B-cell lymphoma: phase I experience from the ALPHA2/ALPHA clinical studies

10.1200/jco-24-01933 · 2025 · External reference

Forks in the road for CAR T and CAR NK cell cancer therapies

10.1038/s41590-023-01659-y · 2023 · External reference

Loss of metabolic fitness drives tumor resistance after CAR-NK cell therapy and can be overcome by cytokine engineering

10.1126/sciadv.add6997 · 2023 · External reference

CAR T cells outperform CAR NK cells in CAR-mediated effector functions in head-to-head comparison

10.1186/s40164-024-00522-6 · 2024 · External reference

IL-15 as a key regulator in NK cell-mediated immunotherapy for cancer: from bench to bedside

10.1016/j.intimp.2024.112156 · 2024 · External reference

CAR NK cell production from human cord blood NK progenitor cells is enhanced by stimulation of the IL-15 receptor

10.1007/s00262-025-04191-0 · 2025 · External reference

Use of CAR-transduced natural killer cells in CD19-positive lymphoid tumors

10.1056/nejmoa1910607 · 2020 · External reference

Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19+ B cell tumors: a phase 1/2 trial

10.1038/s41591-023-02785-8 · 2024 · External reference

Induced pluripotent stem-cell-derived CD19-directed chimeric antigen receptor natural killer cells in B-cell lymphoma: a phase 1, first-in-human trial

10.1016/s0140-6736(24)02462-0 · 2025 · External reference

Dual antigen–targeted off-the-shelf NK cells show durable response and prevent antigen escape in lymphoma and leukemia

10.1182/blood.2021015184 · 2022 · External reference

Co-expression of IL-15 and CCL21 strengthens CAR-NK cells to eliminate tumors in concert with T cells and equips them with PI3K/AKT/mTOR signal signature

10.1136/jitc-2024-010822 · 2025 · External reference

Interaction kinetics with transcriptomic and secretory responses of CD19-CAR natural killer-cell therapy in CD20 resistant non-hodgkin lymphoma

10.1038/s41375-019-0663-x · 2020 · External reference

IL-27-engineered CAR.19-NK-92 cells exhibit enhanced therapeutic efficacy

10.1016/j.jcyt.2024.06.001 · 2024 · External reference

Precision enhancement of CAR-NK cells through non-viral engineering and highly multiplexed base editing

2024 · External reference

CD70-targeted iPSC-derived CAR-NK cells display potent function against tumors and alloreactive T cells

2025 · External reference

CD70-specific CAR NK cells expressing IL-15 for the treatment of CD19-negative B-cell malignancy

10.1182/bloodadvances.2023012202 · 2024 · External reference

Selective cytotoxicity of single and dual anti-CD19 and anti-CD138 chimeric antigen receptor-natural killer cells against hematologic malignancies. Xu B, ed

10.1155/2021/5562630 · 2021 · External reference

Two for one: targeting BCMA and CD19 in B-cell malignancies with off-the-shelf dual-CAR NK-92 cells

10.1186/s12967-022-03326-6 · 2022 · External reference